Oxygenta Pharmaceutical Ltd. logo

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH)

Market Closed
11 Aug, 22:00
MSE MSE
63. 40
+7.6
+13.6201%
1.79B Market Cap
- P/E Ratio
- Div Yield
20,547 Volume
0 Eps
55.8
Previous Close
Add Transaction
Day Range
54.75 64
Year Range
43 102.7
Want to track OXYGENTAPH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

OXYGENTAPH closed today higher at ₹63.4, an increase of 13.6201% from yesterday's close, completing a monthly increase of 26.8254% or ₹13.41. Over the past 12 months, OXYGENTAPH stock gained 16.3303%.
OXYGENTAPH is not paying dividends to its shareholders.
The last earnings report, released on May 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

OXYGENTAPH Chart

People also search for

Tyche Industries Ltd.
125.65
-0.2382%
DHP India Ltd.
518
-1.3239%
Parnax Lab Ltd.
130.25
-2.0677%
Simmonds Marshall Ltd.
193.95
+0.0258%
Gabriel Pet Straps Ltd.
77.17
-4.9982%

Oxygenta Pharmaceutical Ltd. (OXYGENTAPH) FAQ

What is the stock price today?

The current price is ₹63.40.

On which exchange is it traded?

Oxygenta Pharmaceutical Ltd. is listed on MSE.

What is its stock symbol?

The ticker symbol is OXYGENTAPH.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 1.79B.

Has Oxygenta Pharmaceutical Ltd. ever had a stock split?

No, there has never been a stock split.

Oxygenta Pharmaceutical Ltd. Profile

Pharmaceuticals Industry
Healthcare Sector
- CEO
MSE Exchange
INE102E01018 ISIN
India Country
175 Employees
- Last Dividend
- Last Split
- IPO Date
Oxygenta Pharmaceutical Ltd. is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies to address unmet medical needs. The company primarily focuses on developing drugs for rare diseases and chronic conditions, enhancing the quality of life for patients worldwide. Notable for its collaborations with leading research institutions and robust pipeline of drug candidates, Oxygenta actively engages in clinical trials to ensure the efficacy and safety of its products. The pharmaceutical sector, including biotechnology and drug development, is significantly impacted by Oxygenta's contributions, especially as they venture into cutting-edge fields like gene therapy and biologics. Established by a team of seasoned healthcare professionals, Oxygenta Pharmaceutical Ltd. plays a crucial role in advancing medical treatment options, aiming to meet both patient and healthcare provider needs globally. Its strategic partnerships and focus on sustainable drug development practices highlight its commitment to driving innovation in the pharmaceutical industry.

Contact Information

Address: Plot No. B1 and B2
Phone: 91 40 2307 3417